What is Retatrutide?
Retatrutide is a next-generation triple agonist peptide developed to target three key metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This tri-agonist mechanism represents a significant advancement over earlier dual-agonist compounds, offering superior metabolic modulation across multiple pathways.
Mechanism of Action
By activating all three receptors concurrently, Retatrutide delivers a multi-pronged metabolic effect:
- GLP-1 Agonism: Reduces appetite, slows gastric emptying, and improves insulin secretion in a glucose-dependent manner.
- GIP Agonism: Enhances insulin sensitivity, supports fat metabolism, and may amplify the appetite-suppressing effects of GLP-1.
- Glucagon Agonism: Increases energy expenditure and promotes hepatic fat oxidation, directly targeting visceral adiposity.
This combination results in pronounced reductions in body weight, improved glycaemic control, and favourable changes in lipid profiles — effects that exceed those observed with single or dual receptor agonists.
Key Research Findings
- Weight Reduction: Phase 2 clinical trial data reported mean body weight reductions of up to 24% over 48 weeks in the study cohort. These results were observed under controlled trial conditions and are not indicative of outcomes in general use.
- Metabolic Markers: Trial investigators reported reductions in HbA1c, fasting glucose, triglycerides, and LDL cholesterol across study cohorts. These are research observations from a specific trial population.
- Liver Fat: Researchers observed decreases in hepatic fat content in trial participants. The implications for conditions such as NAFLD are under active investigation and no clinical conclusions have been established.
-
Cardiovascular Markers: Some trial participants showed changes in blood pressure and inflammatory markers associated with cardiovascular risk. These findings require further investigation.
Important Notes
Retatrutide is supplied strictly for in vitro and laboratory research purposes. While some human Phase 2 trial data exists in the published literature, this compound is not approved by the TGA or any regulatory body for human use. Information presented here is drawn from published research and is provided for scientific reference only. It does not constitute medical advice and should not inform any therapeutic or clinical decision.